Trinity Biotech plc (TRIB)Healthcare | Medical Devices | Bray, Ireland | NasdaqGS
9.68 USD
-0.07
(-0.718%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 9.60 -0.08 (-0.080%) ⇩ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 2:57 a.m. EDT
The investment case for Trinity Biotech is effectively broken. The company is trapped in a death spiral of deteriorating fundamentals and a catastrophic multi-year price decline. Over the last nine years, the stock has lost 97% of its value, driven by four consecutive years of negative annual returns ending in the most recent period. This persistent decline is not a temporary correction; it reflects a market verdict that the business model is failing to generate value, evidenced by a massive debt load ($138 million) against minimal cash ($5 million), resulting in a negative book value and negative free cash flow. The recent 1-for-30 reverse split was a desperate measure to meet Nasdaq compliance requirements, highlighting the fragility of the capital structure. With no dividend to provide income and a balance sheet that cannot support operations without further dilution or distress, there is no rational basis for a long-term hold. While the price has recently stabilized around $10.60 following the split, the underlying economics remain dire, making this a security to avoid entirely. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 1.025745 |
| MSTL | 1.059833 |
| AutoETS | 1.061966 |
| AutoTheta | 1.062288 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 12% |
| H-stat | 111.91 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.012 |
| Excess Kurtosis | -0.91 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Ex Dividend Date | 2015-06-04 |
| Last Dividend Date | 2015-06-04 |
| Revenue per Share | 70.713 |
| Market Cap | 7,871,118 |
| Forward P/E | -9.40 |
| Beta | 0.99 |
| Profit Margins | -85.36% |
| Website | https://www.trinitybiotech.com |
As of Aug. 22, 2026, 2:57 a.m. EDT: Options activity is negligible and non-directional. There is virtually no open interest or volume in either calls or puts across near-to-medium-term expirations. The lack of liquidity prevents any discernible positioning signal from speculators.
| Date | Dividend | Yield % |
|---|---|---|
| 2015-06-05 | 33.0 | 36.809815 |
| 2014-06-06 | 33.0 | 27.766092 |
| 2013-06-06 | 30.0 | 34.722222 |
| 2012-06-06 | 22.5 | 39.647577 |
| 2011-06-07 | 60.0 | 120.967746 |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.76785713 |
| Address1 | IDA Business Park |
| All Time High | 4,556.25 |
| All Time Low | 7.94 |
| Ask | 12.28 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 35,600 |
| Average Daily Volume3 Month | 58,076 |
| Average Volume | 58,076 |
| Average Volume10Days | 35,600 |
| Beta | 0.988 |
| Bid | 7.02 |
| Bid Size | 2 |
| Book Value | -115.415 |
| City | Bray |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Ireland |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 9.68 |
| Current Ratio | 0.254 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 9.83 |
| Day Low | 9.2976 |
| Display Name | Trinity Biotech |
| Dividend Date | 1,435,708,800 |
| Earnings Call Timestamp End | 1,731,682,800 |
| Earnings Call Timestamp Start | 1,731,682,800 |
| Earnings Timestamp End | 1,756,299,624 |
| Earnings Timestamp Start | 1,755,090,024 |
| Ebitda | -8,243,000 |
| Ebitda Margins | -0.18826 |
| Enterprise To Ebitda | -16.909 |
| Enterprise To Revenue | 3.183 |
| Enterprise Value | 139,379,280 |
| Eps Forward | -1.03 |
| Eps Trailing Twelve Months | -59.57 |
| Esg Populated | 0 |
| Ex Dividend Date | 1,433,462,400 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 11.4794 |
| Fifty Day Average Change | -1.7993994 |
| Fifty Day Average Change Percent | -0.1567503 |
| Fifty Two Week Change Percent | -76.78571 |
| Fifty Two Week High | 52.5 |
| Fifty Two Week High Change | -42.82 |
| Fifty Two Week High Change Percent | -0.81561905 |
| Fifty Two Week Low | 7.94 |
| Fifty Two Week Low Change | 1.7400002 |
| Fifty Two Week Low Change Percent | 0.2191436 |
| Fifty Two Week Range | 7.94 - 52.5 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 719,674,200,000 |
| Five Year Avg Dividend Yield | 1.19 |
| Float Shares | 555,434 |
| Forward Eps | -1.03 |
| Forward P E | -9.398059 |
| Free Cashflow | -11,196,000 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 287 |
| Fullday Change | -0.0699997 |
| Fullday Change Percent | -0.717946 |
| Fullday Price | 9.6 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.38568002 |
| Gross Profits | 16,887,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.13766 |
| Held Percent Institutions | 0.040710002 |
| Implied Shares Outstanding | 813,132 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Dividend Date | 1,433,462,400 |
| Last Dividend Value | 33.0 |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,784,851,200 |
| Last Split Factor | 1:30 |
| Long Business Summary | Trinity Biotech plc, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases, such as syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic measurement of haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. In addition, the company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. It serves public health authorities, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. It has a collaboration agreement with a bioinformatics company to conduct analysis on clinical trial data for EpiCapture, a molecular diagnostics company for developing a non invasive urine based prognostic test for progression to aggressive prostate cancer. It has a strategic collaboration agreement with Echelon Data Centres to develop advanced liquid cooling solutions for AI infrastructure. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland. |
| Long Name | Trinity Biotech plc |
| Market | us_market |
| Market Cap | 7,871,118 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_397947 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -37,376,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 7,928,037 |
| Open | 9.83 |
| Operating Cashflow | -5,929,000 |
| Operating Margins | -0.0998 |
| Payout Ratio | 0.0 |
| Peg Ratio | 0.3 |
| Phone | 353 1 276 9800 |
| Post Market Change | -0.07999992 |
| Post Market Change Percent | -0.82644546 |
| Post Market Price | 9.6 |
| Post Market Time | 1,787,959,805 |
| Previous Close | 9.75 |
| Price Hint | 2 |
| Price To Book | -0.08387125 |
| Price To Sales Trailing12 Months | 0.17976746 |
| Profit Margins | -0.85363 |
| Quick Ratio | 0.109 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.069999695 |
| Regular Market Change Percent | -0.7179456 |
| Regular Market Day High | 9.83 |
| Regular Market Day Low | 9.2976 |
| Regular Market Day Range | 9.2976 - 9.83 |
| Regular Market Open | 9.83 |
| Regular Market Previous Close | 9.75 |
| Regular Market Price | 9.68 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 6,499 |
| Return On Assets | -0.057239998 |
| Revenue Per Share | 70.713 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 813,132 |
| Shares Percent Shares Out | 0.0114 |
| Shares Short | 9,275 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 12,146 |
| Short Name | Trinity Biotech plc |
| Short Percent Of Float | 0.0293 |
| Short Ratio | 0.33 |
| Source Interval | 15 |
| Symbol | TRIB |
| Total Cash | 5,138,000 |
| Total Cash Per Share | 7.612 |
| Total Debt | 137,983,008 |
| Total Revenue | 43,785,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -59.57 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 19.88135 |
| Two Hundred Day Average Change | -10.201349 |
| Two Hundred Day Average Change Percent | -0.51311153 |
| Type Disp | Equity |
| Volume | 6,499 |
| Website | https://www.trinitybiotech.com |
| Zip | A98 H5C8 |